Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy-Reference-Cited by-同舟云学术

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Published:2024-01 Issue:1 Volume:105 Page:189-199
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Zhang Hong,Rizk Dana V.,Perkovic Vlado,Maes Bart,Kashihara Naoki,Rovin Brad^ORCID,Trimarchi Hernán^ORCID,Sprangers Ben,Meier Matthias,Kollins Dmitrij,Papachristofi Olympia,Milojevic Julie,Junge Guido,Nidamarthy Prasanna Kumar,Charney Alan,Barratt Jonathan

Publisher

Elsevier BV

Subject

Nephrology

Reference55 articles.

1. The emerging role of complement proteins as a target for therapy of IgA nephropathy;Rizk;Front Immunol,2019

2. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature;McGrogan;Nephrol Dial Transplant,2011

3. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease;Barbour;Kidney Int,2013

4. IgA nephropathy;Lai;Nat Rev Dis Primers,2016

5. Is IgA nephropathy the same disease in different parts of the world?;Zhang;Semin Immunopathol,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The pathogenesis of IgA nephropathy and implications for treatment;Nature Reviews Nephrology;2024-09-04

2. Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis;Cureus;2024-08-26

3. Therapy of IgA nephropathy: time for a paradigm change;Frontiers in Medicine;2024-08-15

4. Contemporary review of IgA nephropathy;Frontiers in Immunology;2024-08-12

5. Drug repurposing for glomerular diseases: an underutilized resource;Nature Reviews Nephrology;2024-07-31